Articles dans des revues avec comité de lecture (367)
  1. 34. Golstein, S., Muylle, K., Vercruyssen, M., Spilleboudt, C., de Wind, A., & Bron, D. (2018). Long-term follow-up of 2 patients treated with 90Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. European journal of haematology, 101(3), 415-417. doi:10.1111/ejh.13087
  2. 35. Kenis, C., Decoster, L., Flamaing, J., Debruyne, P. P., De Groof, I., Focan, C., Cornélis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J. C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., Specenier, P. M., Jerusalem, G., Praet, J.-P., Vandenborre, K., Lobelle, J. P., Lycke, M., Milisen, K., & Wildiers, H. (2018). Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. Annals of oncology, 29(9), 1987-1994. doi:10.1093/annonc/mdy210
  3. 36. Spilleboudt, C., Thibaut, P., Varlet, É. E., & Bron, D. (2018). Hyperleucocytose maligne ou bénigne? Revue médicale de Bruxelles, 39(4), 291-295.
  4. 37. Crombez, P., Michiels, S., & Bron, D. (2018). Are we ready for intercultural cancer care? Current opinion in oncology, 30(4), 205-211. doi:10.1097/CCO.0000000000000449
  5. 38. Najar, M., Fayyad Kazan, M., Raicevic, G., Fayyad Kazan, H., Meuleman, N., Bron, D., & Lagneaux, L. (2018). Advanced glycation End-Products-, C-Type Lectin- and Cysteinyl/leukotriene-receptors in distinct mesenchymal stromal cell populations: Differential transcriptional profiles in response to inflammation. Cell Journal, 20(2), 250-258. doi:10.22074/cellj.2018.5104
  6. 39. Compte, N., Dumont, L., Bron, D., De Breucker, S., Praet, J. P., Bautmans, I., & Pepersack, T. (2018). White blood cell counts in a geriatric hospitalized population: A poor diagnostic marker of infection. Experimental gerontology, 114, 87-92. doi:10.1016/j.exger.2018.11.002
  7. 40. Najar, M., Fayyad Kazan, M., Meuleman, N., Bron, D., Fayyad Kazan, H., & Lagneaux, L. (2018). Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture. Molecular and cellular biochemistry, 447(1-2), 111-124. doi:10.1007/s11010-018-3297-9
  8. 41. Najar, M., Fayyad Kazan, M., Meuleman, N., Bron, D., Fayyad Kazan, H., & Lagneaux, L. (2018). Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation. Journal of Cell Communication and Signaling. doi:10.1007/s12079-018-0448-4
  9. 42. Najar, M., Krayem, M., Merimi, M., Burny, A., Meuleman, N., Bron, D., Raicevic, G., & Lagneaux, L. (2018). Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts. Inflammation research. doi:10.1007/s00011-018-1131-1
  10. 43. Najar, M., Fayyad Kazan, M., Meuleman, N., Bron, D., Fayyad Kazan, H., & Lagneaux, L. (2017). Immunomodulatory effects of foreskin mesenchymal stromal cells (FSK-MSCs) on natural killer (NK) cells. Journal of cellular physiology. doi:10.1002/jcp.26305
  11. 44. Najar, M., Krayem, M., Meuleman, N., Bron, D., Busser, H., & Lagneaux, L. (2017). Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic. Applied immunohistochemistry & molecular morphology : AIMM. doi:10.1097/PAI.0000000000000629
  12. 45. Libert, Y., Borghgraef, C., Beguin, Y., Delvaux, N., Devos, M., Doyen, C., Dubruille, S., Etienne, A.-M., Liénard, A., Merckaert, I., Reynaert, C., Slachmuylder, J.-L., Straetmans, N., Van Den Neste, E., Bron, D., & Razavi, D. (2017). Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study. Psycho-oncology, 26(12), 2086-2093. doi:10.1002/pon.4424
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 Suivant >>